IkappaB Alpha is a Target for the Mitogen-activated 90 KDa Ribosomal S6 Kinase

Overview

Journal EMBO J

Specialties Biotechnology
Molecular Biology

Date 1997 Jun 2

PMID 9214631

Citations 63

Authors

G J Schouten

A C Vertegaal

S T Whiteside

A Israel

M Toebes

J C Dorsman

A J Van Der Eb

A Zantema

Affiliations

Soon will be listed here.

Abstract

The activity of transcription factor NFkappaB is regulated by its subcellular localization. In most cell types, NFkappaB is sequestered in the cytoplasm due to binding of the inhibitory protein IkappaB alpha. Stimulation of cells with a wide variety of agents results in degradation of IkappaB alpha which allows translocation of NFkappaB to the nucleus. Degradation of IkappaB alpha is triggered by phosphorylation of two serine residues, i.e. Ser32 and Ser36, by as yet unknown kinases. Here we report that the mitogen-activated 90 kDa ribosomal S6 kinase (p90rsk1) is an IkappaB alpha kinase. p90rsk1 phosphorylates IkappaB alpha at Ser32 and it physically associates with IkappaB alpha in vivo. Moreover, when the function of p90rsk1 is impaired by expression of a dominant-negative mutant, IkappaB alpha degradation in response to mitogenic stimuli, e.g. 12-O-tetradecanoylphorbol 13-acetate (TPA), is inhibited. Finally, NFkappaB cannot be activated by TPA in cell lines that have low levels of p90rsk1. We conclude that p90rsk1 is an essential kinase required for phosphorylation and subsequent degradation of IkappaB alpha in response to mitogens.

Citing Articles

Phosphorylation of caspase-8 by RSKs via organ-constrained effects controls the sensitivity to TNF-induced death.

He P, Ai T, Qiao M, Yang Z, Han J Cell Death Discov. 2024; 10(1):255.

PMID: 38789425 PMC: 11126741. DOI: 10.1038/s41420-024-02024-0.

Changes in the Acetylcholinesterase Enzymatic Activity in Tumor Development and Progression.

Perez-Aguilar B, Marquardt J, Munoz-Delgado E, Lopez-Duran R, Gutierrez-Ruiz M, Gomez-Quiroz L Cancers (Basel). 2023; 15(18).

PMID: 37760598 PMC: 10526250. DOI: 10.3390/cancers15184629.

RSK1 and RSK2 serine/threonine kinases regulate different transcription programs in cancer.

Yang W, Caliva M, Khadka V, Tiirikainen M, Matter M, Deng Y Front Cell Dev Biol. 2023; 10:1015665.

PMID: 36684450 PMC: 9845784. DOI: 10.3389/fcell.2022.1015665.

p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors.

Maietta I, Peschio F, Buonocore P, Viscusi E, Laudati S, Iannaci G Cancers (Basel). 2023; 15(1).

PMID: 36612117 PMC: 9817759. DOI: 10.3390/cancers15010121.

A Novel Protein-Protein Interaction between RSK3 and IκBα and a New Binding Inhibitor That Suppresses Breast Cancer Tumorigenesis.

Yoon H, Choi S, Park J, Min J, Hyon J, Yang Y Cancers (Basel). 2021; 13(12).

PMID: 34198590 PMC: 8231827. DOI: 10.3390/cancers13122973.

References

Van Der Eb A, Graham F . Assay of transforming activity of tumor virus DNA. Methods Enzymol. 1980; 65(1):826-39. DOI: 10.1016/s0076-6879(80)65077-0. View

McElhinny J, Trushin S, Bren G, Chester N, Paya C . Casein kinase II phosphorylates I kappa B alpha at S-283, S-289, S-293, and T-291 and is required for its degradation. Mol Cell Biol. 1996; 16(3):899-906. PMC: 231071. DOI: 10.1128/MCB.16.3.899. View

Evan G, LEWIS G, Ramsay G, Bishop J . Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol. 1985; 5(12):3610-6. PMC: 369192. DOI: 10.1128/mcb.5.12.3610-3616.1985. View

Sturgill T, Ray L, Erikson E, Maller J . Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature. 1988; 334(6184):715-8. DOI: 10.1038/334715a0. View

Erikson E, Maller J . Substrate specificity of ribosomal protein S6 kinase II from Xenopus eggs. Second Messengers Phosphoproteins. 1988; 12(2-3):135-43. View

Alcorta D, Crews C, Sweet L, Bankston L, Jones S, Erikson R . Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase. Mol Cell Biol. 1989; 9(9):3850-9. PMC: 362446. DOI: 10.1128/mcb.9.9.3850-3859.1989. View

Pinna L . Casein kinase 2: an 'eminence grise' in cellular regulation?. Biochim Biophys Acta. 1990; 1054(3):267-84. DOI: 10.1016/0167-4889(90)90098-x. View

Kerr L, Inoue J, Davis N, Link E, Baeuerle P, Bose Jr H . The rel-associated pp40 protein prevents DNA binding of Rel and NF-kappa B: relationship with I kappa B beta and regulation by phosphorylation. Genes Dev. 1991; 5(8):1464-76. DOI: 10.1101/gad.5.8.1464. View

Fan C, Maniatis T . Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway. Nature. 1991; 354(6352):395-8. DOI: 10.1038/354395a0. View

10.

Inoue J, Kerr L, Kakizuka A, Verma I . I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. Cell. 1992; 68(6):1109-20. DOI: 10.1016/0092-8674(92)90082-n. View

11.

Hatada E, Nieters A, Wulczyn F, Naumann M, Meyer R, Nucifora G . The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. Proc Natl Acad Sci U S A. 1992; 89(6):2489-93. PMC: 48684. DOI: 10.1073/pnas.89.6.2489. View

12.

Meloche S, Pages G, Pouyssegur J . Functional expression and growth factor activation of an epitope-tagged p44 mitogen-activated protein kinase, p44mapk. Mol Biol Cell. 1992; 3(1):63-71. PMC: 275502. DOI: 10.1091/mbc.3.1.63. View

13.

Capobianco A, Chang D, Mosialos G, Gilmore T . p105, the NF-kappa B p50 precursor protein, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells. J Virol. 1992; 66(6):3758-67. PMC: 241161. DOI: 10.1128/JVI.66.6.3758-3767.1992. View

14.

Chung J, Kuo C, Crabtree G, Blenis J . Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992; 69(7):1227-36. DOI: 10.1016/0092-8674(92)90643-q. View

15.

Wulczyn F, Naumann M, Scheidereit C . Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B. Nature. 1992; 358(6387):597-9. DOI: 10.1038/358597a0. View

16.

Beg A, Ruben S, Scheinman R, Haskill S, Rosen C, Baldwin Jr A . I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev. 1992; 6(10):1899-913. DOI: 10.1101/gad.6.10.1899. View

17.

Franzoso G, Bours V, Park S, Kelly K, Siebenlist U . The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature. 1992; 359(6393):339-42. DOI: 10.1038/359339a0. View

18.

Rice N, MacKichan M, Israel A . The precursor of NF-kappa B p50 has I kappa B-like functions. Cell. 1992; 71(2):243-53. DOI: 10.1016/0092-8674(92)90353-e. View

19.

Bressler P, Brown K, Timmer W, Bours V, Siebenlist U, Fauci A . Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants. J Virol. 1993; 67(1):288-93. PMC: 237362. DOI: 10.1128/JVI.67.1.288-293.1993. View

20.

Naumann M, Wulczyn F, Scheidereit C . The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B. EMBO J. 1993; 12(1):213-22. PMC: 413194. DOI: 10.1002/j.1460-2075.1993.tb05647.x. View